Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million
Reuters
Nov 05
Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million
American Well Corporation reported third quarter 2025 subscription revenue of $30.9 million and Amwell Medical Group visit revenue of $21.2 million. The company achieved a gross margin of 52.4%. Net loss was $31.9 million, compared to a net loss of $19.5 million in the previous quarter. Adjusted EBITDA was negative $12.7 million, compared to negative $4.7 million in the second quarter. Total visits reached 1.1 million. For full-year 2025, Amwell updated its revenue guidance to a range of $245 million to $248 million and narrowed its Adjusted EBITDA guidance to negative $45 million to negative $42 million. The company expects Amwell Medical Group visits between 1.3 million and 1.35 million. For the fourth quarter, revenue is expected to be between $51 million and $54 million, with Adjusted EBITDA between negative $15 million and negative $12 million. Amwell reiterated its objective to achieve positive cash flow from operations in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Well Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-264710), on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.